Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate.

Rosario F Di StefanoMarcello TucciFabio TurcoAlessandro SamuellyMaristella BungaroChiara PisanoFrancesca VignaniMara GallicchioGiorgio V ScagliottiMassimo Di MaioConsuelo Buttigliero

Published in: Prostate cancer and prostatic diseases (2021)

Duration of ADT response is an independent prognostic factor of outcome with AA or E.

Keyphrases

prognostic factors
prostate cancer
stem cells
cell therapy